Reports Q1 revenue $42,000 vs. $32,000 last year. Reports cash and cash equivalents totaled $2.1M as of March 31. "Cibus is an excellent strategic fit for Calyxt given our complementary technology platforms, and the merger provides a great opportunity to leverage multiple synergies to drive innovation and shareholder value," said Michael A. Carr, President and CEO. "I am deeply proud of the significant accomplishments made by our team and their commitment to further the science of biotechnology and synthetic biology in significant ways."
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CLXT:
- Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Reborn Coffee appoints Koschak to new advisory board
- Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
- Calyxt announces effectiveness of registration statement on Form S-4
- Calyxt reports Q4 EPS (6c) vs. (18c) last year